GLP-1 coverage in New York (2026)

Medicaid rules, licensing, compounding, and cash prices, each with its source

Reviewed by the WeighedHealth Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.

Content current as of September 2026; updated when guidance or availability changes.

Last verified September 15, 2026by WeighedHealth Editorial Team against primary sources

New York Medicaid

NY Medicaid (NYRx) excludes drugs used for weight loss under 18 NYCRR §505.3(g)(3). GLP-1s are covered only for Medicaid-covered indications such as type 2 diabetes.

Source: NYRx notification on GLP-1 coverage

Commercial plans set their own rules. See the criteria each carrier publishes on our insurance coverage pages.

Compounded GLP-1s

On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.

Source: FDA press announcement (April 30, 2026)
Source: Federal Register 91 FR 23431 (May 1, 2026)
Source: Federal Register: comment period extended (June 26, 2026)

Background: our guide to compounding rules.

Cash prices without insurance

NovoCare Pharmacy sells Wegovy pens to cash-pay patients for $349 a month ($199 a month for the first two months for new patients through December 31, 2026). LillyDirect sells Zepbound vials for $299 (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg) a month when refilled on time.

Source: NovoCare Pharmacy: Wegovy offer
Source: LillyDirect: Zepbound

Adult obesity rate: CDC Adult Obesity Prevalence Maps (BRFSS 2024).

GLP-1 in New York: common questions

Does New York Medicaid cover Wegovy or Zepbound for weight loss?+

Not covered. NY Medicaid (NYRx) excludes drugs used for weight loss under 18 NYCRR §505.3(g)(3). GLP-1s are covered only for Medicaid-covered indications such as type 2 diabetes.

Is compounded semaglutide still legal in New York?+

Compounding rules for semaglutide and tirzepatide are set federally, not by New York. On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.

What does Wegovy or Zepbound cost without insurance in New York?+

Manufacturer cash prices are the same in every state. NovoCare Pharmacy sells Wegovy pens to cash-pay patients for $349 a month ($199 a month for the first two months for new patients through December 31, 2026). LillyDirect sells Zepbound vials for $299 (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg) a month when refilled on time.